February 27, 2021
Business News

Atomwise Receives a $2.3M Grant to Develop New Therapies for Drug Resistant Malaria and Tuberculosis

SAN FRANCISCO–()–Atomwise, the leader in using artificial intelligence (AI) for small molecule drug discovery, announced today $2.3M in grant funding for AI-based discovery of antimalarial and anti-tuberculosis therapies from the Bill & Melinda Gates Foundation. The grant funding will be used to discover novel compounds that can advance the development of novel antimalarial and anti-tuberculosis small molecule therapies in collaboration with the Gates Foundation’s global network of partners and funded investigators. Atomwise will provide AI-based drug discovery support to leading researchers to translate their biological discoveries into novel therapies.

“Atomwise’s expertise in AI drug discovery has the…

Click here to view the original article.

Related Posts

You might also like ...

Sixpoint Partners Serves as Exclusive Placement Agent for CORE Industrial Partners Fund II
Strategy Analytics: Operating Systems for Autonomous Driving Face a Technology and Methodology Transition